These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 1597723
1. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC. J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723 [Abstract] [Full Text] [Related]
2. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA. J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685 [Abstract] [Full Text] [Related]
3. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J, Weiden P. Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986 [Abstract] [Full Text] [Related]
11. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D. J Nucl Med; 1993 Dec 01; 34(12):2111-9. PubMed ID: 8254397 [Abstract] [Full Text] [Related]
12. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I. J Nucl Med; 1993 Feb 01; 34(2):260-7. PubMed ID: 8429345 [Abstract] [Full Text] [Related]
13. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG. J Nucl Med; 1993 Jun 01; 34(6):908-17. PubMed ID: 8509857 [Abstract] [Full Text] [Related]
14. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G. Clin Cancer Res; 1995 Dec 01; 1(12):1447-54. PubMed ID: 9815943 [Abstract] [Full Text] [Related]
16. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA. Cancer; 1997 Dec 15; 80(12 Suppl):2360-70. PubMed ID: 9406684 [Abstract] [Full Text] [Related]
17. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ. Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726 [Abstract] [Full Text] [Related]